6月5日，葛兰素史克盘中上涨3.01%，报51.22美元/股，成交额1.69亿美元。
消息面上，GSK近期在欧洲肝病学会（EASL）年会上公布乙肝新药贝普若韦生（Bepirovirsen）两项全球III期临床试验积极结果，数据同步发表于《新英格兰医学杂志》。研究显示，该药6个月治疗后总体功能性治愈率达19%，低基线病毒活性人群治愈率达26%，中国亚组中HBsAg≤1000 IU/mL患者治愈率高达35%，安慰剂组为0%。
此外，该药已在中国再次提交上市申请并获受理，纳入优先审评，GSK预计2027年上半年获中国药监局审批决定。杰富瑞预测其峰值年销售额达15亿美元，GSK内部预期更为乐观，有望突破27亿美元。制药行业整体表现强劲，默沙东涨4.67%、礼来涨4.37%、诺和诺德涨4.21%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.